Tissue Repair
TB-500
Thymosin Beta-4 fragment
Chases the same goal as BPC-157 — helping the body heal — but works throughout the body rather than at one injury site, which is why the two often get used together. Same evidence gap too: animals only, no human trials.
Systemic healing , usually paired with BPC-157.
How well studied
Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied
Mostly animal studies or very small early trials in humans. We don't really know yet how it behaves in people.
Heightened caution: this compound carries unresolved regulatory, safety or supply-chain concerns in the UK. Nothing here is a recommendation to use it.
How it works
Rather than working in one spot, this helps repair cells travel to wherever they're needed around the body — the main difference from BPC-157.
Regulates a cell-movement protein (actin) to help repair cells migrate throughout the body rather than staying at one injury site.
Reported benefits
- Whole-body healing support and reduced scar tissue in animal studies
- Supports flexibility and systemic vascular repair
Who it's typically used for
Timeline to results
Dosage
No established human dose — same evidence gap as BPC-157.
Side effects
- Injection site reactionsreported
- Dizzinessreported
- Nauseareported
- Sourcing purityunverified across grey-market supply
Getting it in the UK
Still legal for a doctor to prescribe, but it hasn't been officially approved for this specific use. Uncommon, and comes down to a specialist's own judgement.
MHRA: the UK government body that checks a medicine is safe and actually works before doctors are allowed to prescribe it.
Content freshness
- Last reviewed
- 11 Aug 2026
- Regulatory status last checked
- 11 Aug 2026